Novo Nordisk (NVO.US) expands weight loss drug to younger demographic: STEP Young trial shows semaglutide significantly reduces childhood obesity rates

智通财经2026/09/07 12:26

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to news from Zhitong Finance APP, Novo Nordisk (NVO.US) announced on Monday that in a late-stage clinical trial, if child participants fully adhered to the treatment plan, the active ingredient of its blockbuster weight-loss drug Wegovy—semaglutide—enabled 40.4% of obese children aged 6 to under 12 to no longer be classified as obese after 68 weeks.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Novo Nordisk (NVO.US) expands weight loss drug to younger demographic: STEP Young trial shows semaglutide significantly reduces childhood obesity rates

You may also like

Crypto prices